Elevance Health (NYSE:ELV) CFO Sells $4,658,335.92 in Stock

Elevance Health, Inc. (NYSE:ELV) CFO Mark Kaye sold 10,584 shares of the firm’s stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the transaction, the chief financial officer directly owned 19,919 shares in the company, valued at approximately $8,766,949.47. This represents a 34.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Elevance Health Stock Performance

ELV traded down $5.23 on Friday, hitting $440.05. 1,144,956 shares of the company traded hands, compared to its average volume of 1,603,155. The company has a 50 day moving average of $407.53 and a 200-day moving average of $390.54. The company has a quick ratio of 1.52, a current ratio of 1.47 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $95.43 billion, a PE ratio of 19.56, a PEG ratio of 2.12 and a beta of 0.70. Elevance Health, Inc. has a 12-month low of $274.84 and a 12-month high of $450.69.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The company had revenue of $50.44 billion during the quarter, compared to analysts’ expectations of $49.28 billion. During the same period last year, the firm earned $6.03 EPS. The firm’s revenue for the quarter was up .7% on a year-over-year basis. Sell-side analysts anticipate that Elevance Health, Inc. will post 29.00 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health’s payout ratio is currently 30.58%.

Institutional Investors Weigh In On Elevance Health

Several institutional investors have recently made changes to their positions in the stock. Meiji Yasuda Asset Management Co Ltd. acquired a new position in Elevance Health during the second quarter worth $2,086,000. Stoneridge Investment Partners LLC purchased a new stake in Elevance Health during the second quarter worth $970,000. State Street Corp grew its holdings in Elevance Health by 1.3% in the second quarter. State Street Corp now owns 10,426,610 shares of the company’s stock valued at $4,032,283,000 after purchasing an additional 137,914 shares during the last quarter. State of Wyoming acquired a new stake in Elevance Health in the second quarter valued at $1,765,000. Finally, Farther Finance Advisors LLC increased its position in shares of Elevance Health by 27.1% in the third quarter. Farther Finance Advisors LLC now owns 11,826 shares of the company’s stock valued at $4,598,000 after buying an additional 2,518 shares in the last quarter. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Guggenheim raised their target price on shares of Elevance Health from $460.00 to $485.00 and gave the stock a “buy” rating in a research note on Thursday. Royal Bank Of Canada boosted their price target on shares of Elevance Health from $424.00 to $455.00 and gave the stock a “sector perform” rating in a research note on Thursday. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. UBS Group raised their price objective on shares of Elevance Health from $460.00 to $523.00 and gave the company a “buy” rating in a research report on Thursday. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $451.00 price objective on shares of Elevance Health in a research report on Friday. Fifteen analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $455.57.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
• Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
• Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
• Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
• Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
• Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
• Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
• Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.